论文部分内容阅读
[目的]探讨BRAF~(V600E)基因突变与乳头状甲状腺癌(PTC)淋巴结转移的相关性。[方法]通过第四军医大学图书馆文献管理数据库检索中国生物医学文献数据库、中国学术期刊全文数据库(CNKI)和万方数据库,收集2005年1月至2015年12月发表的关于BRAF~(V600E)在PTC中表达及其与PTC临床病理特征或淋巴结转移相关性的中文研究资料。采用Revman Manager5.3软件对研究结果进行Meta分析。通过异质性检验选择固定效应模型或随机效应模型计算合并的比值比(OR值)及其95%置信区间(95%CI),并进行敏感性分析和发表偏倚评估。[结果]根据纳入标准、剔除标准,本文最终纳入35篇文献进行Meta分析,共计病例3404例,BRAF~(V600E)突变型组1978例,BRAF~(V600E)野生型组1426例。合并后合并效应量OR=1.87(95%CI:1.61~2.17,P<0.00001)。[结论 ]BRAF~(V600E)与PTC淋巴结转移呈明显正相关,BRAF~(V600E)突变可显著提高PTC患者淋巴结转移的发生概率。
[Objective] To investigate the relationship between BRAF ~ (V600E) gene mutation and lymph node metastasis of papillary thyroid carcinoma (PTC). [Method] The databases of Chinese Biomedical Literature, Chinese Academic Journal Full-text Database (CNKI) and Wanfang Database were searched through the database of literature management of the Library of Fourth Military Medical University to collect the data of BRAF ~ (V600E) published from January 2005 to December 2015 ) In PTC and its clinical and pathological features of PTC or lymph node metastasis related to Chinese research data. Revman Manager5.3 software was used to conduct meta-analysis of the results. The pooled odds ratio (OR) and its 95% confidence interval (95% confidence interval) were calculated by heterogeneity test using fixed effect model or random effect model, and sensitivity analysis and publication bias assessment were performed. [Results] According to the inclusion criteria and the exclusion criteria, 35 articles were finally included in the meta-analysis. A total of 3404 cases were included, including 1978 cases in the BRAF V600E mutant group and 1426 cases in the BRAF V600E wild-type group. Combined effect after combination OR = 1.87 (95% CI: 1.61-2.17, P <0.00001). [Conclusion] There is a positive correlation between BRAF V600E and PTC lymph node metastasis. The mutation of BR600 V600E can significantly increase the incidence of lymph node metastasis in patients with PTC.